Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Characteristics of the study cohort (elderly on asthma medicine)

From: Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified

Study group

Total

Mean age (SD)a

Males (%)

Montelukastb (%)

Total drugs in DDDs (SD)c

All subjects

203,473

75.2 (9.7)

89,755 (44.1)

23,636 (11.6)

5.1 (4.6)

Montelukast

23,636

73.1 (9.0)

8964 (37.9)

-

6.3 (4.3)

Dementia medicine

6453

83.6 (7.7)

2502 (38.8)

602 (9.3)

5.6 (3.2)

Nursing homed

5970

77.8 (10.4)

2463 (41.3)

507 (8.5)

4.2 (3.5)

Death

61,434

82.7 (9.5)

31,152 (50.7)

5514 (9.0)

7.1 (6.3)

Parkinson’s medicine

7140

76.1 (9.3)

2849 (39.9)

955 (13.4)

6.3 (3.9)

Diabetes medicine

23,747

74.8 (9.1)

11,920 (50.2)

2887 (12.2)

7.8 (4.3)

  1. aAge in 2014
  2. bAt least two prescriptions
  3. cMean Defined Daily Doses (DDDs) prescribed of any drug
  4. dIt was assumed that a majority of those who did not receive any prescription for more than a year were admitted to a nursing home. Living in a nursing home can be used as a proxy for cognitive decline in that some 80% of Norwegian nursing home residents have dementia [11]